Medical, Pharmaceuticals, Biotech & Healthcare · Corporate Naming Intelligence
Hong Kong Biotech & Genomics Corporate Directory
100 Registered Entities
86HC Statutory Naming & Admittance Essence
Hong Kong represents Asia's largest biotech capital hub. Due diligence audits drug pipeline IP, clinical trial status, and Chapter 18A eligibility.
Statutory Basis & Admittance
Legal Reference: HKEX Main Board Listing Rules Chapter 18A (Pre-revenue Biotech)
Regulatory Tier:
Standard Corporate Title
Due Diligence & Verification Focus
Inspect clinical trial filings, PCT patent portfolio, and HKEX Chapter 18A biotech listing prerequisites.
Statutory Regulatory Authority
Standard corporate entity title with no single mandatory licence court. Review annual returns for verified business activities.
Frequently Asked Questions on Hong Kong "Biotech & Genomics" Entities
Q1: What are the statutory requirements for incorporating a "Biotech & Genomics" entity in Hong Kong?
A: Hong Kong represents Asia's largest biotech capital hub. Due diligence audits drug pipeline IP, clinical trial status, and Chapter 18A eligibility.
Q2: How to conduct anti-fraud due diligence on "Biotech & Genomics" entities before business cooperation?
A: Inspect clinical trial filings, PCT patent portfolio, and HKEX Chapter 18A biotech listing prerequisites. In addition, it is strongly advised to inspect the latest Annual Return and Certified True Copy (CTC) of the Business Registration Certificate.
Q3: If a "Biotech & Genomics" entity shows status "Dissolved", does it still hold due diligence value?
A: It retains significant legal verification and historical credit tracing value. For dissolved entities with historical litigation, debt disputes, or trademark squatting, historical directors registers, Articles of Association, and official winding-up dossiers remain accessible via 86hc.